Marksans Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 26, 2026, recommended Final Dividend of Rs. 0.90 per equity share.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Marksans Pharma's Board approved FY 2025-26 standalone revenue of Rs. 14,450 million (up 17% YoY) and consolidated revenue of Rs. 29,509 million (up 13% YoY). Standalone PAT grew 60% to Rs. 3,007 million while consolidated PAT rose 10% to Rs. 4,201 million. The Board recommended a final dividend of Rs. 0.90 per equity share (90% on face value of Re. 1) for FY 2025-26, subject to shareholder approval at the upcoming AGM. The statutory auditors gave an unmodified opinion on both standalone and consolidated financial results. Two new wholly-owned subsidiaries were formed in Europe and Canada during the year.
The strong 60% jump in standalone PAT and healthy revenue growth reflect solid operational performance. The recommended 90% dividend payout signals confidence in sustained profitability and cash generation, which could positively influence investor sentiment.